Eosinophils in inflammatory bowel disease pathogenesis: an ROS-centric view
- PMID: 40860650
- PMCID: PMC12370722
- DOI: 10.3389/falgy.2025.1608202
Eosinophils in inflammatory bowel disease pathogenesis: an ROS-centric view
Abstract
Eosinophils (Eos), long recognized for their roles in allergy and helminth defense, are now emerging as key players in gastrointestinal immune regulation. In inflammatory bowel disease (IBD), eosinophils are frequently elevated in both blood and intestinal tissues, yet their functional significance has been underexplored. This review reexamines the role of eosinophils in IBD pathogenesis, integrating recent insights into mucosal immunity and tissue homeostasis. We outline the shift in perspective from viewing eosinophils solely as inflammatory effectors to recognizing their dual roles in inflammation and repair. Clinical and experimental findings reveal correlations between eosinophil abundance, activation markers, granule protein release, and disease activity in IBD. Central to our model is the regulatory function of eosinophil-derived reactive oxygen species (ROS), particularly hydrogen peroxide, in maintaining intestinal barrier integrity. Dysregulation of ROS-due to dysbiosis or genetic variants-may impair healing and exacerbate inflammation. We further highlight Siglec-8, an inhibitory receptor on eosinophils that induces apoptosis in response to Neu5Ac-containing sialic acids. This pathway may be disrupted by Neu5Gc, a non-human sialic acid abundant in red meat, potentially linking Western diets to impaired eosinophil regulation. These findings suggest new therapeutic directions targeting Siglec-8 and ROS balance to modulate eosinophil activity and restore intestinal immune homeostasis in IBD. These insights may also help bridge traditionally distinct disease paradigms by highlighting a potential common pathogenic mechanism of epithelial barrier dysfunction and dysregulated eosinophil activation shared between allergic diseases (e.g., asthma, eosinophilic esophagitis) and IBD.
Keywords: Siglec-8; eosinophil; gastrointestinal homeostasis; inflammatory bowel disease; reactive oxygen species.
© 2025 Tomii and Kano.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
T-bet expressing Tr1 cells driven by dietary signals dominate the small intestinal immune landscape.bioRxiv [Preprint]. 2025 Jul 4:2025.06.30.662190. doi: 10.1101/2025.06.30.662190. bioRxiv. 2025. PMID: 40747421 Free PMC article. Preprint.
-
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].Zhonghua Jie He He Hu Xi Za Zhi. 2025 Mar 12;48(3):208-248. doi: 10.3760/cma.j.cn112147-20241013-00601. Zhonghua Jie He He Hu Xi Za Zhi. 2025. PMID: 40050074 Chinese.
-
Management of urinary stones by experts in stone disease (ESD 2025).Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085. Epub 2025 Jun 30. Arch Ital Urol Androl. 2025. PMID: 40583613 Review.
-
Helminth therapy (worms) for induction of remission in inflammatory bowel disease.Cochrane Database Syst Rev. 2014 Jan 20;2014(1):CD009400. doi: 10.1002/14651858.CD009400.pub2. Cochrane Database Syst Rev. 2014. PMID: 24442917 Free PMC article.
References
LinkOut - more resources
Full Text Sources